TPST — Tempest Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1544227 ·
Last close
$0.33
Market Cap
$6.54M
52W High
$9.39
52W Low
$0.30
ADV30
203,896
Next earnings
—
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -2,823,000 -3,629,000 8,761,000 897,000 10,591,000
Jun 2026 0 — -5,250,000 -5,244,000 9,633,000 779,000 10,723,000
Mar 2026 0 — -5,539,000 -27,696,000 10,748,000 1,805,000 9,926,000
Dec 2025 0 — -4,077,000 -4,021,000 16,931,000 7,707,000 10,263,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,730,000
Investing CF
$0
Financing CF
$7,229,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.73
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-275,316,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-40,472,000
Pretax Income TTM
$-40,472,000
Interest Exp TTM
$0
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -26,575,000 -26,262,000 16,931,000 10,263,000 6,668,000 -26,820,000
Dec 2024 0 -42,026,000 -41,843,000 41,488,000 22,362,000 19,126,000 -33,027,000
Dec 2023 0 -29,157,000 -29,491,000 51,603,000 24,835,000 26,768,000 -27,357,000
Dec 2022 0 -34,640,000 -35,709,000 46,089,000 27,978,000 18,111,000 -31,072,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-21,184,000
NetIncome TTM
$-40,472,000
OpCashFlow TTM
—
Assets (Latest)
$9,633,000
Forward EPS
$-1.21

Peers — same industry

TickerNameMarket CapLastDaily %
APRE Aprea Therapeutics, Inc. $6.43M $0.45 —
TOVX Theriva Biologics, Inc. $6.42M $0.14 —
CVKD Cadrenal Therapeutics, Inc. $6.71M $1.88 —
ENVB Enveric Biosciences, Inc. $6.31M $1.41 —
LGVN Longeveron Inc. $6.83M $2.11 —

News headlines (Yahoo Finance, 1h cache)

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-13 21:47 · Yahoo
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
2026-11-11 13:53 · Yahoo
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
2026-10-14 12:00 · Yahoo
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
2026-09-23 12:00 · Yahoo
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
2026-09-15 20:05 · Yahoo
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
2026-09-11 12:00 · Yahoo
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:30 · Yahoo
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:25 · Yahoo
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
2026-07-21 11:00 · Yahoo
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
2026-07-15 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.